

[54] **READILY DISSOLVABLE LYOPHILIZED FIBRINOGEN FORMULATION**

[75] **Inventors:** Peter Fuhge, Lahntal; Norbert Heimbürger, Marburg; Hans-Arnold Stöhr, Wetter; Wolfgang Burk, Gladenbach-Mornshausen, all of Fed. Rep. of Germany

[73] **Assignee:** Behringwerke Aktiengesellschaft, Fed. Rep. of Germany

[21] **Appl. No.:** 639,617

[22] **Filed:** Aug. 10, 1984

**Related U.S. Application Data**

[63] Continuation-in-part of Ser. No. 463,289, Feb. 2, 1983, abandoned.

[30] **Foreign Application Priority Data**

Feb. 4, 1982 [DE] Fed. Rep. of Germany ..... 3203775

[51] **Int. Cl.<sup>4</sup>** ..... A61K 35/14; A61K 31/155; A61K 31/17; A61K 31/195

[52] **U.S. Cl.** ..... 424/101; 514/2; 514/565; 514/588

[58] **Field of Search** ..... 424/177, 101; 514/2

[56] **References Cited**

**U.S. PATENT DOCUMENTS**

4,294,753	10/1981	Urist	424/177
4,298,598	11/1981	Schwarz et al.	424/101
4,362,567	12/1982	Schwarz et al.	424/101
4,377,572	3/1983	Schwarz et al.	424/101
4,414,976	11/1983	Schwarz et al.	128/334
4,440,679	4/1984	Fernandes	424/101

*Primary Examiner*—Donald B. Moyer  
*Assistant Examiner*—Jacqueline M. Stone  
*Attorney, Agent, or Firm*—Finnegan, Henderson, Farabow, Garrett & Dunner

[57] **ABSTRACT**

A solid fibrinogen formulation is described, which formulation contains, in addition to fibrinogen, a substance containing the urea or guanidine radical, and a process for its preparation. This formulation is used for the preparation of a fibrinogen solution which is suitable as an adhesive for human and animal tissue and as a fibrinogen concentrate for intravenous administration.

**5 Claims, No Drawings**